论文部分内容阅读
除了终生胰岛素治疗,重建免疫耐受近年来在1型糖尿病治疗领域越来越受到关注。6月份,Bayhill和基因泰克公司宣布将联合开发一种治疗青少年或1型糖尿病的新药——BHT-3021。在美国,大约有300万人患有这种自身免疫性疾病,每年新确诊病例大约有3万,这一数字每年还以4%的速度在增长。
In addition to lifelong insulin therapy, the reconstruction of immune tolerance has drawn increasing attention in the field of type 1 diabetes treatment in recent years. In June, Bayhill and Genentech announced that they will jointly develop a new drug, BHT-3021, to treat adolescents or type 1 diabetes. In the United States, about 3 million people suffer from this autoimmune disease, with about 30,000 newly diagnosed cases each year, a figure that is growing at a rate of 4% annually.